For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
It was an honour to recognize Judy Needham with the Excellence in Clinical Trials Conduct – Patient Engagement award for her unwavering commitment to patient engagement at CCTG. Judy joined CCTG as a Patient Representative in May 2012 on the Breast Site Committee and became the Chair, CCTG Patient Representatives Committee, in 2014, she successfully led the PRC for over 10 years stepping down this year.
Congratulations to Dr. Moira Rushton, a Medical Oncologist from the Ottawa Hospital Research Institute who has been awarded the Elizabeth Eisenhauer Early Drug Development Young Investigator Award for her work on CCTG IND trials and committees.
“I am truly honored to have been selected as the recipient of this year’s Elizabeth Eisenhauer early drug development young investigator award. My time at CCTG was an invaluable formative experience and continues to meaningfully impact my clinical practice and academic career,” says Dr Rushton.
Congratulations to the PR.24 trial team from Odette Cancer Centre who were presented the Phase III Program Team Award at the 2025 Spring Meeting for their work and dedication to this CCTG led prostate cancer trial. This recognition is awarded to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in this phase III clinical trial to acknowledge their efforts and dedication to the success of clinical trials.
CCTG was pleased to present the Excellence in Clinical Trials Conduct award to Iryna Sokolenko at North York General Hospital for her work to support our trials and contributions to patient-focused research. Iryna is the PCRA for CRC.10 and has been recognized as having exceptional attention to detail who's genuine care made participating in the trial a positive experience for patients. This is presented annually to an individual who exemplifies excellence in clinical trial operations and compliance at their institution.
CCTG will be holding the next CRA Lunch and Learn on Wednesday June 11th, 2025, at 12 pm ET. Session 5 will cover the topic of Understanding the Centre Performance Index (CPI)
The 2025 CCTG Spring Meeting of Participants wrapped up with a record 941 members attending. This dynamic gathering helped shape our future research agenda and celebrated many achievements across our network.
